Glufosfamide or analogues thereof have specific inhibitory effects on cells with specific gene variations, specifically, DNA repairs damaged cells, the cells or tissues at least have one or more genemutations of BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP or ERCC5. The analogues are esters obtained by esterification reaction of one or more hydroxyl groups in glufosfamide molecules with organic acid and inorganic oxyacid; esters obtained by esterification reaction of one or more hydroxyl groups in glufosfamide molecules with amino acid; and salts obtained by reaction of glufosfamide molecules withan acid. Therefore, provided is medical uses of glufosfamide or the analogues thereof in treatment of tumors and cancer diseases of cancer patients with specific gene variations.